Amanote Research
Register
Sign In
CD133+ HCC Cancer Stem Cells Confer Chemoresistance by Preferential Expression of the Akt/PKB Survival Pathway
Oncogene
- United Kingdom
doi 10.1038/sj.onc.1210811
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Genetics
Molecular Biology
Date
September 24, 2007
Authors
S Ma
T K Lee
B-J Zheng
K W Chan
X-Y Guan
Publisher
Springer Science and Business Media LLC
Related search
AKT/PKB Signaling Mechanisms in Cancer and Chemoresistance
Frontiers in Bioscience - Landmark
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
PI3K-PKB/Akt Pathway
Cold Spring Harbor perspectives in biology
Biochemistry
Genetics
Molecular Biology
Activation of PI3K/Akt Pathway by CD133-p85 Interaction Promotes Tumorigenic Capacity of Glioma Stem Cells
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Docetaxel Promotes Cell Apoptosis and Decreases SOX2 Expression in CD133‑expressing Hepatocellular Carcinoma Stem Cells by Suppressing the PI3K/AKT Signaling Pathway
Oncology Reports
Medicine
Cancer Research
Oncology
Mesenchymal Stem Cells Confer Chemoresistance in Breast Cancer via a CD9 Dependent Mechanism
Oncotarget
Oncology
CD133 Regulates PI3K/AKT Signaling in Glioma Stem Cells
Cancer Discovery
Oncology
Molecular Alterations in Apoptotic Pathways After PKB/Akt-mediated Chemoresistance in NCI H460 Cells
British Journal of Cancer
Cancer Research
Oncology
Maspin Suppresses Survival of Lung Cancer Cells Through Modulation of Akt Pathway
Cancer Research and Treatment
Cancer Research
Oncology
STAT3 Is a Key Transcriptional Regulator of Cancer Stem Cell Marker CD133 in HCC
HepatoBiliary Surgery and Nutrition
